One of the biggest weaknesses of the Wall Street research model is that it tends to focus on stocks that are able to make the fastest upward move, failing to really look at which stocks could post strong returns over the long haul. As a result,... read more »
When executives of a company step in and buy its stock, it can provide a glimpse into an overlooked or misunderstood value opportunity. Sadly, these insiders are often lousy market timers. They tend to acquire shares after a stock has lost a... read more »
Volatility is back. The markets slumped badly at the end of last week and have rallied considerably higher thus far this week. From solid corporate earnings to tepid economic reports to deepening troubles in Europe, there’s a whole lot... read more »
There is one huge risk when it comes to owning shares of high-growth companies. No one really knows how far or how close the company is to market saturation, so investors (and Wall Street analysts) are left to trust the company as it keeps issuing... read more »
The best opportunities arise when there is a “divergence from the consensus.” This phrase often refers to analysts’ profit forecasts, and the wide range of estimates spells opportunity if you know on which side of the fence... read more »
In most instances, it pays to focus your investment research on companies that are delivering great results. Rising profits, thanks to market share gains, hot new products, international expansion and other factors often lead to a surging valuation... read more »
Earlier this week, I looked at a range of commodity stocks that look quite attractive in relation to the value of their assets. I focused on Freeport McMoran (NYSE: FCX) as a clear example of a stock that looks quite appealing in the context... read more »
There’s an old saying on Wall Street that investors should look to the income statement for upside and the balance sheet for downside protection. But for mining and energy stocks, this axiom has been spun on its head. Income-statement... read more »
Randal J. Kirk is beside himself right now. The legendary biotech investor, who is now worth more than $2 billion, made a rare misstep by plunking down $14 million (at $10.61 a share) on Halozyme Therapeutics (Nasdaq: HALO) in February, only... read more »
Oh Argentina. Why must you frustrate us so? You’re blessed with so many resources and have so much charm. Yet you can’t help but alienate everyone that you come into contact with. Over the last century, as nations such as Japan,... read more »
LEGAL DISCLAIMER: TopStockAnalysts.com and its parent company, StreetAuthority, LLC, are publishers of financial news and opinions and NOT securities brokers/dealers or investment advisors. You are responsible for your own investment decisions. All information contained in our newsletters or on our web site(s) should be independently verified with the companies mentioned, and readers should always conduct their own research and due diligence and consider obtaining professional advice before making any investment decision. As a condition to accessing our materials and web sites, you agree to our Terms and Conditions of Use, available here, including without limitation all disclaimers of warranties and limitations on liability contained therein. Owners, employees and writers may hold positions in the securities that are discussed in our newsletters or on our web site.
TopStockAnalysts.com
4601 Spicewood Springs Rd. Building 3, Suite 100 Austin, Texas 78759 (512) 501-4002 Copyright © 2006-2011 TopStockAnalysts.com